Hyperkeratosis
Methodology & AI Transparency ⓘ
Hyperkeratosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hyperkeratosis—coded clinically as L57.0 across Skin & Dermatology guidelines—combines topical retinoids/calcineurin/steroid sparing in Hyperkeratosis (L57.0: regimens) with structured follow-up of Affected Body Surface in Hyperkeratosis (L57.0: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L57.0)).
- 2 Real-world patient consensus: Clinical coding for Hyperkeratosis uses ICD-10 L57.0 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Hyperkeratosis (L57.0) utilizes topical retinoids/calcineurin/steroid sparing in Hyperkeratosis (L57.0: regimens).
- 4 Top reported side effects / signs: Objective lab/clinical target for Hyperkeratosis: 25-Hydroxy Vitamin D in Hyperkeratosis (L57.0: & hs-CRP) (25(OH)D 40–65 ng/mL (L57.0)) and Affected Body Surface in Hyperkeratosis (L57.0: Area (BSA /).
Ask our AI Specialists anything about Hyperkeratosis
What Is Hyperkeratosis?
Hyperkeratosis—coded clinically as L57.0 across Skin & Dermatology guidelines—combines topical retinoids/calcineurin/steroid sparing in Hyperkeratosis (L57.0: regimens) with structured follow-up of Affected Body Surface in Hyperkeratosis (L57.0: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L57.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Hyperkeratosis (ICD-10 L57.0) is driven by cutaneous immune skewing in Hyperkeratosis (L57.0: (Th2/IL-4/IL-13 in atopic); specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor Affected Body Surface in Hyperkeratosis (L57.0: Area (BSA /) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Hyperkeratosis (L57.0): recurrent flares triggered in Hyperkeratosis (L57.0: by UV exposure,)
- • Secondary Hyperkeratosis clinical sign: persistent erythematous plaques, in Hyperkeratosis (L57.0: scaly patches, pruritic)
- • Symptom flares in Hyperkeratosis correlating with 25-Hydroxy Vitamin D in Hyperkeratosis (L57.0: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L57.0)
- • Functional skin & dermatology impact requiring topical retinoids/calcineurin/steroid sparing in Hyperkeratosis (L57.0: regimens) evaluation (L57.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hyperkeratosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L57.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Hyperkeratosis (L57.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L57.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Hyperkeratosis (L57.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L57.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Hyperkeratosis (L57.0: ALT (if systemic) | Within baseline reference limits (L57.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hyperkeratosis
Treatment selection for Hyperkeratosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hyperkeratosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Randomized, gold-standard blind, active-controlled, multicentre, phase III: What a 240-Participant Study Found This study showed that LeBA was as effective and safe as OnBA for the treatment of CFL at the same doses. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-07-15 • Phase III Randomized Trial | N = 240 | 88/100 | PMID 33721365 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of the ustekinumab biosimilar, Bmab 1200, versus reference Bmab 1200 and reference ustekinumab had similar efficacy, safety, immunogenicity, and PK in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups. Expert opinion on biological therapy • 2025-08-15 • Phase III Randomized Trial | N = 191 | 88/100 | PMID 40708530 ↗ |
| Can This Approach Help? Inside the Latest Research on Tildrakizumab for moderate-to-severe plaque psoriasis skin flare-ups in Chinese Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups. Chinese medical journal • 2024-05-20 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38192233 ↗ |
| Can This Approach Help? Inside the Latest Research on Serious Gastrointestinal-Related side effects Among Psoriasis Patients Treated No cases of IBD were observed and rates of GI SAEs were low through 4 years of treatment with guselkumab in two large trials of patients with psoriasis. Journal of drugs in dermatology : JDD • 2021-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34397205 ↗ |
| New Insights on Tapinarof cream 1% once daily was well tolerated in adults and children with: What a 813-Participant Study Found Conclusion: Tapinarof was well tolerated locally from first application through Week 8, including on sensitive skin areas. The Journal of dermatological treatment • 2025-12-15 • Phase III Randomized Trial | N = 813 | 87/100 | PMID 39799945 ↗ |
Hyperkeratosis Patient Community & “People Like Me” Threads
Filter Hyperkeratosis community threads and patient logs by age, biological sex, dosage, and treatment duration.